Stem cell transplant shows promise against rare blood cancer
NCT ID NCT02844361
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a stem cell transplant (using the patient's own cells) works better than standard chemotherapy for people with a high-risk form of Waldenström macroglobulinemia, a rare blood cancer. 70 patients in China took part. The goal was to see if the transplant could help them live longer without the cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- autologous stem cell transplantation
- What this could lead to
- If this works, it could offer a more effective way to control high-risk Waldenström macroglobulinemia and improve survival compared to standard chemotherapy.
- What could go wrong
- This is a completed Phase 4 trial with only 70 participants in China, so results may not apply to all patients. Stem cell transplant carries risks like infection and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shuhua Yi
Tianjin, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug duo shows promise for rare blood cancer
- New PET tracer aims to spot hidden cancers without biopsy
- New hope for rare blood cancer: targeted drug shows promise in early trial
- New Two-Step transplant shows promise for blood cancer patients
- New drug targets Hard-to-Treat blood cancers in chinese trial
- New drug combo shows promise for blood cancer patients